

CITATION REPORT

List of articles citing

A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study

DOI: 10.1016/j.jpba.2021.114404

Journal of Pharmaceutical and Biomedical Analysis, 2022, 207, 114404.

Source: <https://exaly.com/paper-pdf/119341232/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT Receptor Agonist for the Treatment of Schizophrenia.. <i>Pharmaceutical Research</i> , 2022, 1	4.5	1
3	Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. <i>CNS Drugs</i> ,	6.7	2
2	Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans.		0
1	A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.		0